Differences between oestrogen receptor activation by oestrogen and antioestrogen. Nature. 1981;292(5820):257-9.ROCHEFORTH, . AND BORGNAJ,. L. ( I98 I ). Differences between oestrogen receptor activation by oestrogen and antiestrogen. ?Vutiire292:257-259....
Oestrogen and progestagen metabolites were measured in the faeces of five female giant anteaters (Myrmecophaga tridactyla), to characterise the oestrous cy... M Patzl,F Schwarzenberger,C Osmann,... - 《Animal Reproduction Science》 被引量: 83发表: 1998年 Use of Progesterone and Estrogen in...
OBJECTIVE: Across a woman's lifetime, variations in hormone levels are known to influence mood and well-being. Whether absolute or changes in hormone level... J Ryan,L Dennerstein,HG Burger,... 被引量: 0发表: 2013年 Effects of estrogen replacement therapy on abdominal fat compartments as ...
Adipose tissue grows by two mechanisms: hyperplasia (cell number increase) and hypertrophy (cell size increase). Genetics and diet affect the relative cont... Junghyo,Jo,Oksana,... - 《Plos Computational Biology》 被引量: 468发表: 2009年 Estrogen, inflammation and cardiovascular risk in women:...
Bocchinfuso WP, Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 1997, 2: 323-334. 10.1023/A:1026339111278. Article CAS PubMed Google Scholar Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML...
We found that a functional oestrogen/ERα signalling pathway was active in VCaP cells, as determined by reporter-based estrogen response element (ERE) luciferase assays in VCaP cells, with ERα and AR overexpression, and E2 or R1881 treatment, respectively, for 48 h (Fig. 2f). To ...
摘要: Investigates the effect of estrogen replacement therapy in women. Use estrogen replacement therapy for postmenopausal osteoporosis prevention; Association of therapy with reduced cardiovascular mortality; Debate over the mediation of estrogen effects....
The minimum dose of exemestane that produces the maximum suppression of plasma estrogen levels is 25 mg/day [63]. In patients failing on tamoxifen, a phase III trial has demonstrated that exemestane (25 mg/day) significantly prolongs TTP and TTF when compared with megestrol acetate (median TTP...
Rosano GMC, Crea F: Chest pain and myocardial ischaemia in syndrome X: new pathogenetic hypotheses. Cor Art Dis 1992; 3: 599 –608 CrossRef Rosano GMC, Kaski JC, Lindsay DC, Collins P, Sarrel PM, Poole-Wilson PA: Syndrome X in women is associated with estrogen deficiency. Eur Heart ...
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer Article Open access 29 November 2022 An emerging generation of endocrine therapies in breast cancer: a clinical perspective Article Open access...